<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01503944</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-133-B03</org_study_id>
    <nct_id>NCT01503944</nct_id>
  </id_info>
  <brief_title>A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)</brief_title>
  <official_title>Detection of Striatal Dopaminergic Degeneration and Neocortical Amyloid Pathology in Patients With Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease, and Healthy Elderly Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the ability to identify individuals with
      dopaminergic degeneration in group of patients with a clinical diagnosis of either dementia
      with Lewy bodies (DLB) or idiopathic Parkinson's disease and to differentiate them from
      Alzheimer's disease (AD) and control subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>18F-AV-133 striatal to occipital standard uptake value ratio</measure>
    <time_frame>Four Weeks</time_frame>
    <description>The ratio of tracer activity in striatal target areas of interest relative to the occipital cortex reference region</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>18F-AV-45 cortical to cerebellar standard uptake value ratio</measure>
    <time_frame>Four Weeks</time_frame>
    <description>The ratio of tracer activity in cortical target areas of interest relative to the cerebellum reference region</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Dementia With Lewy Bodies</condition>
  <condition>Alzheimer's Disease</condition>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Dementia with Lewy Bodies</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Parkinson's disease</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Elderly Volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alzheimer's Disease</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-AV-133</intervention_name>
    <description>185 MBq</description>
    <arm_group_label>Dementia with Lewy Bodies</arm_group_label>
    <arm_group_label>Parkinson's disease</arm_group_label>
    <arm_group_label>Healthy Elderly Volunteers</arm_group_label>
    <arm_group_label>Alzheimer's Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-AV-45</intervention_name>
    <description>185-370 MBq</description>
    <arm_group_label>Dementia with Lewy Bodies</arm_group_label>
    <arm_group_label>Parkinson's disease</arm_group_label>
    <arm_group_label>Healthy Elderly Volunteers</arm_group_label>
    <arm_group_label>Alzheimer's Disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria DLB:

          -  Male or female &gt; 50 years of age

          -  Meet the diagnostic criteria for probable DLB as established by the DLB Consortium
             (McKeith et al., 2005)

        Inclusion Criteria AD:

          -  Male or female &gt; 50 years of age

          -  Meet the NINCDS criteria for probable AD and have a Mini Mental State Examination
             (MMSE) score at screening between 10 and 24 inclusive

        Inclusion Criteria PD:

          -  Male or female &gt; 50 years of age

          -  Have probable PD according to the following criteria (Gelb et al., 1999):

               -  Presence of 2 of the following 3 features: rest tremor, rigidity, bradykinesia;

               -  Documented history of a sustained (&gt;6 months) improvement to Levodopa (L-DOPA) or
                  a dopamine agonist

               -  Absence of atypical clinical features or other possible signs or symptoms
                  suggesting another cause of parkinsonism such as a history of frequent falls as a
                  prominent early feature, localized brain lesion(s) or neuroleptic use

               -  Asymmetric onset

          -  A diagnosis of PD made within the 4 years prior to enrollment

        Normal subjects:

          -  Are males or females &gt; 50 years of age

          -  Have a MMSE score &gt; 29, and are cognitively normal on the psychometric test battery at
             screening

          -  Have no signs or symptoms of clinically meaningful parkinsonism

        Exclusion Criteria:

          -  Have a history or current diagnosis of other neurologic disease

          -  Have evidence of clinically significant cerebrovascular disease

          -  Have evidence from MRI or other biomarker studies that suggests the presence of a CNS
             pathology other than that associated with the study diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Avid Radiopharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2010</study_first_submitted>
  <study_first_submitted_qc>January 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2012</study_first_posted>
  <disposition_first_submitted>August 3, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>August 3, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 14, 2012</disposition_first_posted>
  <last_update_submitted>August 3, 2012</last_update_submitted>
  <last_update_submitted_qc>August 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

